Treatment options are limited for non-muscle-invasive bladder cancer patients having failed BCG treatment who cannot undergo cystectomy. While results from ongoing clinical trials are awaited, data have emerged suggesting that combination of agents having previously demonstrated safety and efficacy in this setting can help a large percentage of our patients. These data should not be ignored.
European urology. 2018 Apr 20 [Epub ahead of print]
Roger Li, Philippe E Spiess, Ashish M Kamat
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .